Open AccessBazedoxifene Suppresses Intracellular Mycobacterium tuberculosis Growth by Enhancing Autophagy
Author(s) -
Qi Ouyang,
Kehong Zhang,
Dong-Xin Lin,
Carl G. Feng,
Yuchen Cai,
Xinchun Chen
Publication year - 2020
Publication title -
msphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.749
H-Index - 39
ISSN - 2379-5042
DOI - 10.1128/msphere.00124-20
Subject(s) - autophagy , tuberculosis , mycobacterium tuberculosis , drug , immunity , intracellular , drug resistance , medicine , immunology , biology , immune system , pharmacology , microbiology and biotechnology , apoptosis , biochemistry , pathology
Since current strategies for the treatment of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) have low efficacy and highly negative side effects, research on new treatments including novel drugs is essential for curing drug-resistant tuberculosis. Host-directed therapy (HDT) has become a promising idea to modulate host cell responses to enhance protective immunity against pathogens. Bazedoxifene (BZA), which belongs to a new generation of SERMs, shows the ability to inhibit the growth of M. tuberculosis in macrophages and is associated with autophagy. Our findings reveal a previously unrecognized antibacterial function of BZA. We propose that the mechanism of SERMs action in macrophages may provide a new potential measure for host-directed therapies against TB.